Dysbiosis may hinder effective tumor immunity and reduce the efficacy of therapies such as immune checkpoint blockade (ICB) in renal cell carcinoma (RCC). CBM588, a product containing live Clostridium butyricum, has shown promise in enhancing ICB effectiveness in metastatic RCC in terms of response rates and progression-free survival. Further research to confirm these findings should take factors such as diet and microbiome composition into account and include predictive biomarkers for patient selection.
European urology focus. 2025 Jan 20 [Epub ahead of print]
Kevin K Zarrabi, Ulka Vaishampayan, Pedro C Barata
Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Philadelphia PA USA., Department of Medicine/Oncology, Rogel Cancer Center, University of Michigan Ann Arbor MI USA., Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University Cleveland OH USA. Electronic address: .